Australia's most trusted
source of pharma news
Posted 10 April 2026 AM
Pharmac has announced new funding for cancer drugs and an antiviral, with the listings expected to ease pressure on the hospital system by reducing the time spent there.
From 1 May treatment options for people living with chronic lymphocytic leukaemia (CLL) will be expanded, with AbbVie's Venclexta funded in combination with Johnson & Johnson's Imbruvica or Roche's Gazyva as a first line treatment option for CLL. Further, access to Imbruvica will be widened as a second line treatment regardless of a patient's specific mutation.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.